biostudies-literatureUnknown26(3)Barreiro ACurrent COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4⁺ and CD8⁺ T cell response and RBD-binding antibodies with neutralizing activity against several variants, and also showediScience106126https://www.ebi.ac.uk/biostudies/studies/S-EPMC9893798biostudies-literaturePreclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.PMC9893798Molas MTrinite BSistere-Oro MBech-Sabat GPradenas EVergara-Alert JPrat Cabanas TPrado JGMoreno ALorca-Oro CRoca MMoros ARoca NDiaz Pedroza JCebollada Rica PPuigvert Molas EOrtiz RBlanco JPerez MFerrer LMadrenas LBarreiro APanosa CPentinat-Pelegrin TPerozo Mur EGonzalez-Gonzalez LSegales JIglesias-Fernandez JPol Vilarrassa EFernandez APalmada JFernandez-Bastit LRodon JMarch RMarfil SBarretina JClotet BCanete MMeyerhans AAmpudia Carrasco RCapdevila Larripa SCorominas JRosales Salgado YPrenafeta AGarriga CLoubat-Casanovas JfalsePreclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4⁺ and CD8⁺ T cell response and RBD-binding antibodies with neutralizing activity against several variants, and also showed2023-01-01T00:00:00Z2023 Mar2026-05-28T20:09:49.741Z2025-04-04T21:09:33.861ZS-EPMC98937983674808610.1016/j.isci.2023.106126